S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
NASDAQ:STOK

Stoke Therapeutics (STOK) Stock Price, News & Analysis

$13.50
-0.67 (-4.73%)
(As of 03/28/2024 ET)
Today's Range
$12.20
$14.25
50-Day Range
$4.12
$14.17
52-Week Range
$3.35
$16.40
Volume
4.56 million shs
Average Volume
2.27 million shs
Market Capitalization
$625.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.63

Stoke Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
45.4% Upside
$19.63 Price Target
Short Interest
Healthy
12.79% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.59
Upright™ Environmental Score
News Sentiment
0.54mentions of Stoke Therapeutics in the last 14 days
Based on 43 Articles This Week
Insider Trading
Selling Shares
$212,852 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.27) to ($2.69) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.65 out of 5 stars

Medical Sector

81st out of 939 stocks

Pharmaceutical Preparations Industry

29th out of 443 stocks

STOK stock logo

About Stoke Therapeutics Stock (NASDAQ:STOK)

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company is also developing STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is based in Bedford, Massachusetts.

STOK Stock Price History

STOK Stock News Headlines

Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Why Is Stoke Therapeutics (STOK) Stock Up 99% Today?
See More Headlines
Receive STOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/07/2023
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:STOK
Fax
N/A
Employees
117
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$19.63
High Stock Price Target
$35.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+45.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Net Income
$-101,070,000.00
Pretax Margin
-1,192.47%

Debt

Sales & Book Value

Annual Sales
$8.78 million
Book Value
$4.69 per share

Miscellaneous

Free Float
39,162,000
Market Cap
$625.05 million
Optionable
Optionable
Beta
0.68
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Edward M. Kaye M.D.Dr. Edward M. Kaye M.D. (Age 75)
    Ph.D., CEO & Director
    Comp: $931.21k
  • Dr. Adrian R. Krainer Ph.D. (Age 65)
    Co-Founder & Independent Director
    Comp: $44k
  • Mr. Stephen J. Tulipano CPA (Age 65)
    MBA, Chief Financial Officer
    Comp: $619.09k
  • Dr. Barry S. Ticho FACC (Age 63)
    M.D., Ph.D., Chief Medical Officer
    Comp: $688.83k
  • Ms. Isabel Aznarez Ph.D. (Age 51)
    Co-Founder & Group VP of Discovery Research
  • Dr. Huw M. Nash Ph.D. (Age 57)
    COO & Chief Business Officer
    Comp: $429.67k
  • Mr. Eric Rojas
    Head of Investor Relations
  • Mr. Jonathan Allan J.D. (Age 34)
    Corporate Secretary & General Counsel
  • Ms. Dawn Kalmar (Age 46)
    Chief Communications Officer
  • Ms. Joan Wood
    Chief Human Resources Officer

STOK Stock Analysis - Frequently Asked Questions

Should I buy or sell Stoke Therapeutics stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" STOK shares.
View STOK analyst ratings
or view top-rated stocks.

What is Stoke Therapeutics' stock price target for 2024?

9 brokers have issued 12 month target prices for Stoke Therapeutics' shares. Their STOK share price targets range from $12.00 to $35.00. On average, they anticipate the company's share price to reach $19.63 in the next twelve months. This suggests a possible upside of 45.4% from the stock's current price.
View analysts price targets for STOK
or view top-rated stocks among Wall Street analysts.

How have STOK shares performed in 2024?

Stoke Therapeutics' stock was trading at $5.26 at the beginning of 2024. Since then, STOK shares have increased by 156.7% and is now trading at $13.50.
View the best growth stocks for 2024 here
.

When is Stoke Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our STOK earnings forecast
.

How were Stoke Therapeutics' earnings last quarter?

Stoke Therapeutics, Inc. (NASDAQ:STOK) released its earnings results on Monday, August, 7th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.63) by $0.06. The company earned ($2.48) million during the quarter, compared to analysts' expectations of $4 million.

What ETFs hold Stoke Therapeutics' stock?

ETFs with the largest weight of Stoke Therapeutics (NASDAQ:STOK) stock in their portfolio include Morningstar US Small Growth (MSGR) and Simplify Propel Opportunities ETF (SURI).Global X Genomics & Biotechnology ETF (GNOM).

What other stocks do shareholders of Stoke Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Gossamer Bio (GOSS), Editas Medicine (EDIT), Alector (ALEC), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Precision BioSciences (DTIL), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), Marvell Technology (MRVL) and Invitae (NVTA).

When did Stoke Therapeutics IPO?

Stoke Therapeutics (STOK) raised $100 million in an initial public offering on Wednesday, June 19th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity was co-manager.

Who are Stoke Therapeutics' major shareholders?

Stoke Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include RTW Investments LP (9.25%), Vanguard Group Inc. (3.69%), Vanguard Group Inc. (3.69%), Goldman Sachs Group Inc. (3.12%), Granahan Investment Management LLC (2.55%) and Northern Trust Corp (0.58%). Insiders that own company stock include Barry Ticho, Edward M Md Kaye, Huw M Nash, Jonathan Allan and Stephen J Tulipano.
View institutional ownership trends
.

How do I buy shares of Stoke Therapeutics?

Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:STOK) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners